Christine M. Heske, M.D.

Center for Cancer Research
National Cancer Institute

Building 10-CRC, Room 1-3816
Bethesda, MD 20892-1104
240-760-6197
christine.heske@nih.gov

Investigator

Pediatric Oncology Branch

NIH Distinguished Scholar

Head, Translational Sarcoma Biology Group

RESEARCH SUMMARY

Dr. Heske is a physician-scientist with a laboratory and clinical research focus on novel therapeutic agents for pediatric sarcomas including rhabdomyosarcoma and Ewing sarcoma. Specifically, she seeks to identify and evaluate new therapeutic targets for these cancers by understanding the mechanisms behind therapeutic resistance and developing strategies to overcome such resistance through targeting tumor metabolism and DNA damage repair.

Areas of Expertise

DNA Damage and Repair

Early Phase Clinical Trials

Clinical Trials
Research
Publications
Biography
Job Vacancies
Team
News

Open - Not yet Recruiting

Phase 1/2 study of Vincristine and Temozolomide in combination with PEN-866 for adolescents and young adults with relapsed or refractory solid tumors

Protocol ID
NCI000092

Investigator

Christine M. Heske, M.D.

Referral Contacts

Anne Goodwin

240.760.6195

Research

Dr. Heske is a clinician and physician-scientist with an active translational and clinical research program focused on sarcoma treatments. Her goal is to improve outcomes for patients with pediatric sarcomas by understanding mechanisms of resistance and identifying and evaluating new therapeutic targets.

Major projects in her lab focus on understanding and targeting the biologic vulnerabilities in tumor metabolism and DNA repair in pediatric sarcomas such as Ewing sarcoma and rhabdomyosarcoma.

In addition to conducting preclinical research, Dr. Heske is invested in translating promising laboratory findings into early-phase clinical trials for young patients with sarcoma. She currently leads a phase I/II trial for patients with rhabdomyosarcoma that uses a promising combination therapy and is developing several additional trials based on work in her lab.

Publications

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

Gibson AE, Yeung C, Issaq SH, Collins VJ, Gouzoulis M, Zhang Y, Ji J, Mendoza A, Heske CM.

Oncogenesis. 9(9): 80, 2020. [ Journal Article ]

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, Rai G, Urban DJ, Johnson MS, Benavides GA, Squadrito GL, Yohe ME, Lei H, Eldridge S, Hamre J 3rd, Dowdy T, Ruiz-Rodado V, Lita A, Mendoza A, Shern JF, Larion M, Helman LJ, Stott GM, Krishna MC, Hall MD, Darley-Usmar V, Neckers LM, Heske CM.

Cancer Res. 79(19): 5060-5073, 2019. [ Journal Article ]

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ.

Clin Cancer Res. 23(23): 7301-7311, 2017. [ Journal Article ]

The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma

Heske CM, Yeung C, Mendoza A, Baumgart JT, Edessa LD, Wan X, Helman LJ.

Transl Oncol. 9(6): 540-547, 2016. [ Journal Article ]

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma

Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ.

Oncotarget. 7(40): 65540-65552, 2016. [ Journal Article ]

Biography

Investigator

Christine M. Heske, M.D.

After completing her undergraduate work at Harvard University, Dr. Heske received her M.D. from The George Washington University School of Medicine and Health Sciences. She completed her pediatric internship and residency at Brown University/Hasbro Children's Hospital, followed by her fellowship training at the combined National Cancer Institute-Johns Hopkins University Pediatric Hematology and Oncology program, where she served as Chief Fellow and conducted post-doctoral work in the lab of Dr. Lee Helman. In 2016, Dr. Heske began her own group as a Physician-Scientist Early Investigator in the Pediatric Oncology Branch. She was promoted to Investigator in 2021 and currently leads the Translational Sarcoma Biology Group.

She is the recipient of numerous awards including a ASCO Young Investigator Award, a Children's Cancer Foundation Research Award, and an NIH Distinguished Mentor Award. Dr. Heske holds board certifications in General Pediatrics and Pediatric Hematology/Oncology.